Key Highlights

  • Marker Therapeutics (NASDAQ:MRKR) reported a third-quarter net loss of USD 1,844,472, against USD 1,998,662 a year earlier, or USD 0.10 per share versus USD 0.12.
  • Cash and cash equivalents were USD 9,039,785 on September 30, 2026, down from USD 16,068,048 at the end of 2025.
  • Grant income rose to USD 1,292,996 in the quarter from USD 1,232,938, and a new USD 4.2 million award was announced in July 2026.
  • Management expects current cash to fund operations into the second quarter of 2027 and cites substantial going-concern doubt.

Lower Research Spending Trims the Quarterly Loss

Marker Therapeutics (NASDAQ:MRKR) filed its Quarterly Report on November 16, 2026. The third-quarter net loss narrowed to USD 1,844,472 from USD 1,998,662, as total operating expenses eased to USD 3,229,253 from USD 3,369,664. Research and Development spending fell to USD 2,172,263 from USD 2,345,843, while general and administrative costs rose to USD 1,056,990 from USD 1,023,821. Interest income was USD 91,785, down from USD 138,064. The company has no recurring product revenue, so grant income is the only line offsetting its costs. Loss from operations was USD 3,229,253 versus USD 3,369,664, and nine-month G&A expense was USD 3,431,002 compared with USD 3,338,200. Net loss per share improved to USD 0.10 from USD 0.12 on roughly 16.7 million shares outstanding.

MAR-T Cell Pipeline Funded Largely Through Government Grants

The company is a clinical-stage immuno-oncology Business developing multi-antigen recognizing T cell therapies for blood cancers and solid tumors. Its lead candidate, MT-601, is in a Phase 1 study in relapsed lymphoma, and the company is also pursuing pancreatic cancer. Grant income reached USD 2,726,266 over nine months against USD 2,443,225 a year earlier. In July 2026 it received notice of a USD 4.2 million award from the Department of War for large B-cell lymphoma, and in September 2026 a USD 2.6 million FDA Orphan Products grant for MT-601 in pancreatic cancer. No funds had been received from either award at the filing date, Kincellis Advanced Therapies is contracted to provide technology transfer and cGMP Manufacturing for MT-601 for its APOLLO study, and the filing refers to a larger pivotal lymphoma trial planned for 2026. Earlier awards include a CPRIT acute myeloid leukemia grant of about USD 13.1 million, of which USD 11.8 million had been received, and several National Institutes of Health small business grants of USD 2.0 million each.

Nine-Month Loss Falls by a Third While Cash Declines

The nine-month net loss was USD 6,849,979 against USD 10,460,410, as research and development spending dropped to USD 6,491,151 from USD 9,658,322 and the prior-year period carried a USD 453,135 loss on ending a vendor agreement. Net cash used in operations was USD 7.6 million. Cash and equivalents of USD 9,039,785 plus USD 387,973 of restricted cash and total liabilities were USD 1,996,412. The filing says cash should last into the second quarter of 2027 without further grants, and management is weighing a securities issue and new grant applications. About 16.7 million common shares were outstanding, and no Preferred Shares were issued.

Where Things Stand

The smaller loss reflects lower research spending, not new revenue, and Marker Therapeutics (NASDAQ:MRKR) continues to rely on grants while its cash balance shrinks. The filing's guidance of funding into the second quarter of 2027, and the going-concern language that comes with it, frame the next steps: receipt of the Department of War and FDA grant funds, any Capital raise, and progress in the MT-601 lymphoma and pancreatic cancer programs.